Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Expanding incentives for coordinated, patient-centered care: Implications for neurologists.

Mantyh WG, Cohen BH, Ciccarelli L, Philpot LM, Jones LK Jr.

Neurol Clin Pract. 2018 Feb;8(1):62-66. doi: 10.1212/CPJ.0000000000000426.

PMID:
29517056
2.

Control of type III protein secretion using a minimal genetic system.

Song M, Sukovich DJ, Ciccarelli L, Mayr J, Fernandez-Rodriguez J, Mirsky EA, Tucker AC, Gordon DB, Marlovits TC, Voigt CA.

Nat Commun. 2017 May 9;8:14737. doi: 10.1038/ncomms14737.

3.

Structure of the mycobacterial ESX-5 type VII secretion system membrane complex by single-particle analysis.

Beckham KS, Ciccarelli L, Bunduc CM, Mertens HD, Ummels R, Lugmayr W, Mayr J, Rettel M, Savitski MM, Svergun DI, Bitter W, Wilmanns M, Marlovits TC, Parret AH, Houben EN.

Nat Microbiol. 2017 Apr 10;2:17047. doi: 10.1038/nmicrobiol.2017.47.

PMID:
28394313
4.

Are PEEK-on-Ceramic Bearings an Option for Total Disc Arthroplasty? An In Vitro Tribology Study.

Siskey R, Ciccarelli L, Lui MK, Kurtz SM.

Clin Orthop Relat Res. 2016 Nov;474(11):2428-2440.

5.

The BTB domains of the potassium channel tetramerization domain proteins prevalently assume pentameric states.

Smaldone G, Pirone L, Pedone E, Marlovits T, Vitagliano L, Ciccarelli L.

FEBS Lett. 2016 Jun;590(11):1663-71. doi: 10.1002/1873-3468.12203. Epub 2016 May 24.

6.

Management of oral anticancer drugs: feasibility and patient approval of a specific monitoring program.

Cirillo M, Lunardi G, Coati F, Ciccarelli L, Alestra S, Mariotto M, Micheloni B, Cassandrini PA, Inno A, Magarotto R, Nicodemo M, Picece V, Turazza M, Gori S, Venturini M.

Tumori. 2014 May-Jun;100(3):243-8. doi: 10.1700/1578.17190.

PMID:
25076232
7.

Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.

Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Ciccarelli L, D'Angelo A, Fogari E, Maffioli P.

Can J Physiol Pharmacol. 2013 Sep;91(9):724-32. doi: 10.1139/cjpp-2012-0300. Epub 2013 Apr 23.

PMID:
23984793
8.

Structure and conformational variability of the mycobacterium tuberculosis fatty acid synthase multienzyme complex.

Ciccarelli L, Connell SR, Enderle M, Mills DJ, Vonck J, Grininger M.

Structure. 2013 Jul 2;21(7):1251-7. doi: 10.1016/j.str.2013.04.023. Epub 2013 Jun 6.

9.

Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.

Pharmacotherapy. 2013 Aug;33(8):817-26. doi: 10.1002/phar.1301. Epub 2013 Jun 6.

PMID:
23744726
10.

The Latest Lessons Learned from Retrieval Analyses of Ultra-High Molecular Weight Polyethylene, Metal-on-Metal, and Alternative Bearing Total Disc Replacements.

Kurtz SM, Toth JM, Siskey R, Ciccarelli L, Macdonald D, Isaza J, Lanman T, Punt I, Steinbeck M, Goffin J, van Ooij A.

Semin Spine Surg. 2012 Mar 1;24(1):57-70.

11.

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.

Diabet Med. 2012 Dec;29(12):1515-23. doi: 10.1111/j.1464-5491.2012.03699.x.

PMID:
22540883
12.

Structural and dynamic properties of incomplete immunoglobulin-like fold domains.

Berisio R, Ciccarelli L, Squeglia F, De Simone A, Vitagliano L.

Protein Pept Lett. 2012 Oct;19(10):1045-53. Review.

PMID:
22533620
13.

Comparison of in vivo and simulator-retrieved metal-on-metal cervical disc replacements.

Kurtz SM, Ciccarelli L, Harper ML, Siskey R, Shorez J, Chan FW.

Int J Spine Surg. 2012 Dec 1;6:145-56. doi: 10.1016/j.ijsp.2012.03.002. eCollection 2012.

14.

Tilt-pair analysis of images from a range of different specimens in single-particle electron cryomicroscopy.

Henderson R, Chen S, Chen JZ, Grigorieff N, Passmore LA, Ciccarelli L, Rubinstein JL, Crowther RA, Stewart PL, Rosenthal PB.

J Mol Biol. 2011 Nov 11;413(5):1028-46. doi: 10.1016/j.jmb.2011.09.008. Epub 2011 Sep 12.

15.

SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.

Gao DA, Xiong Z, Heim-Riether A, Amodeo L, August EM, Cao X, Ciccarelli L, Collins BK, Harrington K, Haverty K, Hill-Drzewi M, Li X, Liang S, Margarit SM, Moss N, Nagaraja N, Proudfoot J, Roman R, Schlyer S, Keenan LS, Taylor S, Wellenzohn B, Wiedenmayer D, Li J, Farrow NA.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5039-43. doi: 10.1016/j.bmcl.2010.07.036. Epub 2010 Jul 15.

PMID:
20675133
16.

Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.

Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA.

Horm Metab Res. 2010 Aug;42(9):663-9. doi: 10.1055/s-0030-1255036. Epub 2010 Jun 17.

PMID:
20560108
17.

Angiotensin II receptor blockers and insulin resistance.

Ciccarelli L.

Hypertens Res. 2010 Aug;33(8):779. doi: 10.1038/hr.2010.99. Epub 2010 Jun 10. No abstract available.

PMID:
20535122
18.

Exenatide versus glibenclamide in patients with diabetes.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Diabetes Technol Ther. 2010 Mar;12(3):233-40. doi: 10.1089/dia.2009.0141.

PMID:
20151774
19.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
20.

Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.

Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF.

J Clin Pharm Ther. 2009 Jun;34(3):267-76.

PMID:
19650249
21.

Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.

Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G.

Ann Oncol. 2009 Dec;20(12):1929-35. doi: 10.1093/annonc/mdp287. Epub 2009 Jul 17.

PMID:
19622510
22.

Synbeads porous-rigid methacrylic support: application to solid phase peptide synthesis and characterization of the polymeric matrix by FTIR microspectroscopy and high resolution magic angle spinning NMR.

Sinigoi L, Bravin P, Ebert C, D'Amelio N, Vaccari L, Ciccarelli L, Cantone S, Basso A, Gardossi L.

J Comb Chem. 2009 Sep-Oct;11(5):835-45. doi: 10.1021/cc900050t.

PMID:
19594112
23.

Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study.

Derosa G, Salvadeo SA, Mereu R, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Tinelli C.

Diabetes Technol Ther. 2009 Mar;11(3):159-69. doi: 10.1089/dia.2008.0101.

PMID:
19267581
24.

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.

Derosa G, Mereu R, Salvadeo SA, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AF.

Intern Med. 2009;48(5):265-71. Epub 2009 Mar 2.

25.

Matrix metalloproteinase-2 and -9 levels in obese patients.

Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF.

Endothelium. 2008 Jul-Aug;15(4):219-24. doi: 10.1080/10623320802228815.

PMID:
18663625
26.

Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.

Derosa G, Salvadeo SA, D'Angelo A, Fogari E, Ragonesi PD, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AF.

Arch Med Res. 2008 May;39(4):412-9. doi: 10.1016/j.arcmed.2007.12.009. Epub 2008 Mar 10.

PMID:
18375253
27.

What is the correlation of in vivo wear and damage patterns with in vitro TDR motion response?

Kurtz SM, Patwardhan A, MacDonald D, Ciccarelli L, van Ooij A, Lorenz M, Zindrick M, O'Leary P, Isaza J, Ross R.

Spine (Phila Pa 1976). 2008 Mar 1;33(5):481-9. doi: 10.1097/BRS.0b013e318165e3be.

28.

Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R.

Hypertens Res. 2007 May;30(5):387-94.

PMID:
17587750
29.

Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.

Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R.

Hypertens Res. 2006 Nov;29(11):849-56.

PMID:
17345784
30.

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

Intern Med J. 2007 Feb;37(2):79-86.

PMID:
17229249
31.

Polyethylene wear and rim fracture in total disc arthroplasty.

Kurtz SM, van Ooij A, Ross R, de Waal Malefijt J, Peloza J, Ciccarelli L, Villarraga ML.

Spine J. 2007 Jan-Feb;7(1):12-21. Epub 2006 Dec 6.

PMID:
17197327
32.

Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.

Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Fogari E, Salvadeo SA, Ferrari I, Gravina A, Fassi R, Fogari R.

Clin Drug Investig. 2006;26(9):529-39.

PMID:
17163286
33.

Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Cicero AF.

J Int Med Res. 2006 Sep-Oct;34(5):545-55.

PMID:
17133785
34.

Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.

Fogari R, Preti P, Zoppi A, Lazzari P, Corradi L, Fogari E, Ciccarelli L, Derosa G.

Eur J Clin Pharmacol. 2006 Oct;62(10):817-22. Epub 2006 Aug 2.

PMID:
16896785
35.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
36.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
37.

Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.

Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF.

Endothelium. 2006 May-Jun;13(3):227-31.

PMID:
16840178
38.

Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension.

Derosa G, Cicero AF, D'Angelo A, Tinelli C, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Fogari R.

J Cardiovasc Pharmacol. 2006 Apr;47(4):508-12.

PMID:
16680063
39.

Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.

Derosa G, Cicero AF, Dangelo A, Gaddi A, Ragonesi PD, Piccinni MN, Salvadeo S, Ciccarelli L, Pricolo F, Ghelfi M, Ferrari I, Montagna L, Fogari R.

Hypertens Res. 2005 Nov;28(11):917-24.

PMID:
16555581
40.

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.

Diabetes Obes Metab. 2006 Mar;8(2):197-205.

PMID:
16448524
41.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
42.

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R.

Diabetes Res Clin Pract. 2005 Jul;69(1):5-13. Epub 2004 Dec 29.

PMID:
15955382
43.
44.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
45.

Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.

Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R.

J Cardiovasc Pharmacol. 2005 Jun;45(6):599-604.

PMID:
15897788
46.

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.

Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.

Diabetes Obes Metab. 2005 Jan;7(1):47-55.

PMID:
15642075
48.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
49.

Patient satisfaction and pain management: an educational approach.

Innis J, Bikaunieks N, Petryshen P, Zellermeyer V, Ciccarelli L.

J Nurs Care Qual. 2004 Oct-Dec;19(4):322-7.

PMID:
15535537

Supplemental Content

Loading ...
Support Center